Roth Sees Limited Use of Cytori's (CYTX) Cell Therapy in Japan as Key Milestone; Affirms at 'Buy'
Tweet Send to a Friend
Roth Capital affirms Cytori Therapeutics (Nasdaq: CYTX) at Buy with a price target of $11 after the company announced that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
